Literature DB >> 18809477

Activation of the protein p7OS6K via ERK phosphorylation by cholinergic muscarinic receptors stimulation in human neuroblastoma cells and in mice brain.

Julie Deguil1, Marie-Christine Perault-Pochat, François Chavant, Claire Lafay-Chebassier, Bernard Fauconneau, Stéphanie Pain.   

Abstract

Stimulation of cholinergic muscarinic receptors has been shown to provide substantial protection from DNA damage, oxidative stress and mitochondrial impairment, insults that may be encountered by neurons in development, aging, or neurodegenerative diseases. A study recently indicated that the activation of muscarinic receptors in astrocytoma cells modified the expression of the kinase p70S6K involved in the translational control. The translational control is in part regulated by a cascade of phosphorylation affecting proteins of the anti-apoptotic way controlled by mTOR (mammalian target of rapamycin) and the pro-apoptotic way controlled by PKR. The aim of our study was to investigate the effect of cholinergic muscarinic stimulation by an agonist oxotremorine on the anti-apoptotic way of translational control, in human neuroblastoma cells and in mice brain. Our results showed that muscarinic receptor activation significantly increased the expression of phosphorylated p70S6K, eIF4E and ERK without modification of mTOR activity in neuroblastoma cells and in cerebral cortex and hippocampus of mice, suggesting a stimulation of protein synthesis. Our findings support the notion that synaptic activity, through activation of neurotransmitter receptors, can provide substantial support of cellular survival mechanisms and suggest that loss of such synaptic input increases vulnerability to insult-induced programmed cell death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809477     DOI: 10.1016/j.toxlet.2008.08.012

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

Review 1.  Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.

Authors:  Merouane Bencherif
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

2.  Crosstalk between VEGFR2 and muscarinic receptors regulates the mTOR pathway in serum starved SK-N-SH human neuroblastoma cells.

Authors:  Jacob Edelstein; Tianfeng Hao; Qin Cao; Leon Morales; Patricia Rockwell
Journal:  Cell Signal       Date:  2010-09-16       Impact factor: 4.315

3.  Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.

Authors:  Woo-Young Kim; Ludmila Prudkin; Lei Feng; Edward S Kim; Bryan Hennessy; Ju-Seog Lee; J Jack Lee; Bonnie Glisson; Scott M Lippman; Ignacio I Wistuba; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

4.  Neuroprotective and Antioxidant Role of Oxotremorine-M, a Non-selective Muscarinic Acetylcholine Receptors Agonist, in a Cellular Model of Alzheimer Disease.

Authors:  Giuseppa Mudò; Valentina Di Liberto; Domenico Nuzzo; Monica Frinchi; Costanza Giardina; Miriana Scordino; Mariachiara Zuccarini; Chiara De Simone; Marta Di Carlo; Natale Belluardo
Journal:  Cell Mol Neurobiol       Date:  2022-09-03       Impact factor: 4.231

5.  GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.

Authors:  Rong-Jian Liu; Manabu Fuchikami; Jason M Dwyer; Ashley E Lepack; Ronald S Duman; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2013-05-17       Impact factor: 7.853

Review 6.  Consolidation and translation regulation.

Authors:  Shunit Gal-Ben-Ari; Justin W Kenney; Hadile Ounalla-Saad; Elham Taha; Orit David; David Levitan; Iness Gildish; Debabrata Panja; Balagopal Pai; Karin Wibrand; T Ian Simpson; Christopher G Proud; Clive R Bramham; J Douglas Armstrong; Kobi Rosenblum
Journal:  Learn Mem       Date:  2012-08-16       Impact factor: 2.460

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.